ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

Other authors

Institut Català de la Salut

[de Azambuja E] Institut Jules Bordet and l’Université Libre de Bruxelles (U.LB), Brussels, Belgium. [Trapani D] European Institute of Oncology (IEO) IRCCS, Milan, Italy. [Loibl S] GBG Forschungs GmbH, Neu-Isenburg, Germany. [Delaloge S] Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France. [Senkus E] Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland. [Criscitiello C] European Institute of Oncology IRCCS, Milan, Italy. [Cortes J] IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona). Vall d'Hebron institute of Oncology (VHIO), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-09-20T09:50:36Z

2021-09-20T09:50:36Z

2020-05-20



Abstract

COVID-19; Recomanacions adaptades per l'ESMO; Càncer de mama


COVID-19; Recomendaciones adaptadas de ESMO; Cáncer de mama


COVID-19; ESMO adapted recommendations; Breast cancer


The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes. The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice. We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine. The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.

Document Type

Article


Published version

Language

English

Publisher

BMJ

Related items

ESMO Open;5

https://doi.org/10.1136/esmoopen-2020-000793

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)